The metabolism pharmaceuticals market is predicted to increase due to the availability of a wide range of therapies such as small molecule medications and enzyme replacement therapy, as well as the rising prevalence of metabolic illnesses and a strong pipeline. Manufacturers are working hard to create novel treatments for a variety of metabolic illnesses.
Request PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1955
Various pipeline items, such as NeoGAA GZ402666 (Sanofi) in phase 3, AT-982 (Audentes Therapeutics) in phase 3, and BMN 701 (BioMarin Pharmaceutical, Inc.) in phase 2 clinical trial, are projected to drive this market throughout the forecast period. Amicus Therapeutics was granted with orphan drug designation for its investigational combination drug therapy ATB200/AT2221, in November 2017. This drug is intended to cure Pompe disease (acid maltase deficiency or AMD). in March 2018, Shire plc entered into a preclinical research collaboration with NanoMedSyn— French biotech company—to develop enzyme replacement treatment for a lysosomal storage disorder based on NanoMedSyn’s synthetic derivative technology named AMFA. Lixte Biotechnology Holdings, Inc., has LB-201/LB-205 in the preclinical stage, JCR Pharmaceuticals Co. Ltd. filed for JR-051 in Japan in 2017, and has many other products in the pipeline for treatment of metabolic diseases. Moreover, manufacturers such as Pharming Group NV and Orphazyme ApS also have products in the pipeline for metabolic diseases.
Request For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1955
The metabolism medications market is predicted to rise due to partnerships and collaboration between individual organisations for research and development of effective therapies. Shire Plc, for example, established a collaboration with ArmaGen in 2014 to develop the AGT-182 medication for the treatment of hunter syndrome. In addition, research supported by the National Institute of Neurological Disorders and Stroke (NINDS) in 2017 showed that viral-delivered gene therapy can prevent the buildup of materials in brain cells and improve memory and learning. High return on investments, health insurance coverage, and various reimbursement policies for such costly drugs are influencing pharmaceutical companies to invest in drug development. For example, in 2015, Orphan Product Grants Program funded 18 new grant awards from 92 grant applications and provided funding and support to around 67 ongoing clinical study projects related to rare disease. Furthermore, initiatives from governments such as Sweden’s, the Netherlands’, and South Korea’s that focus on approving reimbursement guidelines for individuals undergoing enzyme replacement therapy (ERT) are expected to boost the metabolic drugs market growth in the near future (as enzyme replacement therapy is a major therapy in the market).
Key Takeaways of the Metabolism Drugs Market:
- Due to partnerships and collaborations for drug development by key manufacturers such as Shire Plc, the global metabolism medicines market is predicted to grow at a CAGR of 3% from 2018 to 2026. The expansion of the metabolism pharmaceuticals market is projected to be driven by enzyme replacement therapies. Due to extensive research & development activities by major players in the area, North America is likely to hold a prominent position in the metabolism medicines market over the projection period. Major players operating in the global metabolism drugs market include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
Buy This Research Study Report For Quick Access@ https://www.coherentmarketinsights.com/insight/buy-now/1955
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- PEST Analysis
- PORTER’s Analysis
- Regulatory Scenario
- Market Dynamics
- Global Metabolism Drugs Market, By Therapy Type, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Substrate Reduction Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Small Molecule Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Metabolism Drugs Market, By Application, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Glycogen Metabolism Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Lipid Metabolism Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Amino Acid Metabolism Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Metabolism Drugs Market, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Metabolism Drugs Market, By Regions, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2026
- North America
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of APAC
- Latin America
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- Central Africa
- South Africa
- North Africa
- Middle East
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Introduction
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837